In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds

Journal of Clinical Microbiology

Volumn 51, Issue 8, 2013, Pages 2608-2616

  Pfaller, Michael A ^a   Messer, Shawn A ^a   Rhomberg, Paul R ^a   Jones, Ronald N ^a   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISAVUCONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA FERMENTATI; CANDIDA GLABRATA; CANDIDA INTERMEDIA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; FUNGAL STRAIN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOULD; MOUSE; NEUTROPENIA; NONHUMAN; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; YEAST;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; HUMANS; MICROBIAL SENSITIVITY TESTS; NITRILES; OPPORTUNISTIC INFECTIONS; PYRIDINES; TRIAZOLES;

EID: 84880613296     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00863-13     Document Type: Article

References (41)

1. Guinea J, Bouza E. 2008. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Future Microbiol. 3:603-615.
2. Pasqualotto AC, Thiele KO, Goldani LZ. 2010. Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. Curr. Opin. Investig. Drugs 11:165-174.
3. Thompson GR, III, Wiederhold NP. 2010. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 170: 291-313.
4. Livermore J, Hope W. 2012. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin. Drug Metab. Toxicol. 8:759-765.
5. Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, Brown T, Roehrle M. 2006. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob. Agents Chemother. 50:286-293.
6. Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. 2009. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob. Agents Chemother. 53:3453-3461.
7. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. 2008. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob. Agents Chemother. 52: 1396-1400.
8. Guinea J, Recio S, Escribano P, Pelaez T, Gama B, Bouza E. 2010. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. Antimicrob. Agents Chemother. 54:4012-4015.
9. Perkhofer S, Lechner V, Lass-Florl C. 2009. In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 53:1645-1647.
10. Rudramurthy SM, Chakrabarti A, Geertsen E, Mouton JW, Meis JF. 2011. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagn. Microbiol. Infect. Dis. 71:370-377.
11. Seifert H, Aurbach U, Stefanik D, Cornely O. 2007. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob. Agents Chemother. 51:1818-1821.
12. Thompson GR, III, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. 2009. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J. Antimicrob. Chemother. 64:79-83.
13. Verweij PE, Gonzalez GM, Wiedrhold NP, Lass-Florl C, Warn P, Heep M, Ghannoum MA, Guinea J. 2009. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. J. Chemother. 21:272-281.
14. Yamazaki T, Inagaki Y, Fujii T, Ohwada J, Tsukazaki M, Umeda I, Kobayashi K, Shimma N, Page MG, Arisawa M. 2010. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan. Int. J. Antimicrob. Agents 36:324-331.
15. Illnait-Zaragozi MT, Martinez GF, Curfs-Breuker I, Fernandez CM, Boekhout T, Meis JF. 2008. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob. Agents Chemother. 52:1580-1582.
16. Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA. 2009. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J. Antimicrob. Chemother. 63:161-166.
17. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
18. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, Van Burik JA, Wingard JR, Patterson TF. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
19. Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. 2005. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 80:868-871.
20. Arendrup MC, Bruun B, Christensen JJ, Fuursted K, Johansen HK, Kjaeldgaard P, Knudsen JD, Kristensen L, Moller J, Nielsen L, Rosenvinge FS, Roder B, Schonheyder HC, Thomsen MK, Truberg K. 2011. National surveillance of fungemia in Denmark (2004 to 2009). J. Clin. Microbiol. 49:325-334.
21. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. 2011. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob. Agents Chemother. 55:532-538.
22. Pfaller MA. 2012. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125:S3-S13.
23. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. 2012. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J. Clin. Microbiol. 50:1199-1203.
24. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. 2010. Breakthrough invasive candidiasis in patients on micafungin. J. Clin. Microbiol. 48:2373-2380.
25. Sun HY, Singh N. 2010. Characterization of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int. J. Antimicrob. Agents 35:211-218.
26. Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36:1-53.
27. Pfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50:2846-2856.
28. Espinel-Ingroff A, Diekema DJ, Canton E, Fothergill A, Johnson EM, Pelaez T, Pfaller MA, Rinaldi MG, Turnidge JD. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48:3251-3257.
29. Hazen KC, Howell SA. 2007. Candida, Cryptococcus, and other yeasts of medical importance, p 1762-1788. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed), Manual of clinical microbiology, 9th ed, vol 2. ASM Press, Washington, DC.
30. Larone DH. 2002. Medically important fungi: a guide to identification, 4th ed. ASM Press, Washington, DC.
31. Castanheira M, Woosley LN, Diekema DJ, Jones RN, Pfaller MA. 2013. Candida guilliermondii and other species of Candida misidentified as Candida famata: assessment by Vitek2, ITS sequence analysis and matrixassisted laser desorption ionization-time of flight mass spectrometry in two global surveillance programs. J. Clin. Microbiol. 51:117-124.
32. Leaw SN, Chang HC, Sun HF, Barton R, Bouchara JP, Chang TC. 2006. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J. Clin. Microbiol. 44:693-699.
33. Linton CJ, Borman AM, Cheung G, Holmes AD, Szekely A, Palmer MD, Bridge PD, Campbell CK, Johnson EM. 2007. Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United Kingdom Mycology Reference Laboratory. J. Clin. Microbiol. 45:1152-1158.
34. Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. 2012. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program. Mycopathologia 174:259-271.
35. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts: third edition. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
36. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts: third informational supplement. M27-S3Clinical and Laboratory Standards Institute-Wayne, PA.
37. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning DW, Donnelly JP, Dromer F, Fegela W, Lass-Floerl C, Moore C, Richardson M, Sandven P, Vergrak V, Verweij P. 2008. EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
38. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: second edition. M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
39. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
40. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ. 2009. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J. Clin. Microbiol. 47:3323-3325.
41. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. 2011. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagn. Microbiol. Infect. Dis. 71:252-259.